NCT05838066View on ClinicalTrials.gov

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

PHASE3RecruitingINTERVENTIONAL
Enrollment

880

Participants

Timeline

Start Date

July 23, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2027

Conditions
First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Interventions
DRUG

Recombinant Humanized Bispecific antibody against HER2，KN026

IV infusion

DRUG

HB1801

IV infusion

DRUG

Pertuzumab

840 mg loading dose followed by 420 mg per cycle, D1 Q3W, IV infusion

DRUG

Trastuzumab

8 mg/kg loading dose followed by 6 mg/kg per cycle, D1 Q3W, IV infusion

DRUG

Docetaxel

75 mg/m\^2, D1 Q3W, IV infusion

Trial Locations (1)

Unknown

RECRUITING

Clinical Trials Information Group, Beijing

All Listed Sponsors
lead

Shanghai JMT-Bio Inc.

INDUSTRY